Differences in Uptravi maintenance doses had no impact on the risk of hospitalization among adults with PAH, a claims ...

Normally, these nasty effects are kept in check by another chemical called prostacyclin. But prostacyclin is made, in part, with the help of Cox-2 enzymes -- the enzymes that drugs like Celebrex ...

We recently published a list of 16 Best Mid Cap Growth Stocks To Buy Now. In this article, we are going to take a look at ...

Investigators say more research is warranted to optimize management of patients with pulmonary arterial hypertension (PAH) ...

Future Cardiol. 2013;9(3):335-349. Research into prostacyclin analogs for the treatment of WHO Group 2 PH has been limited, likely due to the early termination of the FIRST trial. [55] This study ...

United Therapeutics is also in search of an effective medicine with trepostinil, a prostacyclin mimetic, currently in phase 3 development for IPF. As is Bristol-Myers Squibb, recently announcing ...

The clinical significance and frequency of adverse events with tNSAIDs in the lower GI tract have been increasingly reported, but are much more poorly characterized than those from the upper GI ...

Can eating fat be good for us? Some fatty acid molecules actually play a crucial role in maintaining our health and cellular functions. By the early twentieth century, scientists and doctors ...

Most participants were receiving either three (61%) or two (35%) background drugs for PAH, and 40% were receiving prostacyclin infusions. The mean time from PAH diagnosis was 8.8 years.

They also produce signaling molecules like nitric oxide and prostacyclin to maintain vascular balance. However, EC ...

In The Lancet Respiratory Medicine, Olivier Sitbon and colleagues1 present the results of a randomised, phase 2b clinical trial (ELEVATE-2) that compared the safety and efficacy of pulmonary arterial ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that five presentations and one poster across its commercial and development portfolio will be presented ...